Trials / Completed
CompletedNCT03228017
Subclinical Cardiovascular Disease in Psoriatic Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic disease and measures of vascular function. 2) Evaluate the association between moderate to severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional medications used in cardiovascular disease (CVD) prevention such as aspirin and statins affect vascular function and thrombotic risk in those with moderate to severe psoriatic disease.
Detailed description
Cardiovascular disease (CVD) remains the leading cause of death in the US. Five modifiable risk factors: smoking, hyperlipidemia, diabetes, hypertension and obesity, account for 50% of CVD mortality between the ages of 45 - 79.1 These traditional cardiac risk factors dictate who to treat with primary prevention measures but do not take into account patient-specific disease states such as psoriatic disease including psoriasis and psoriatic arthritis, which predispose to chronic inflammation. Patients with psoriatic disease have an increased risk of atherosclerotic heart disease and myocardial infarctions compared to matched controls.
Conditions
- Cardiovascular Diseases
- Myocardial Infarction
- Atherosclerotic Cardiovascular Disease
- Thrombotic Vascular Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin and/or Atorvastatin | This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation. |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2019-04-01
- Completion
- 2019-04-01
- First posted
- 2017-07-24
- Last updated
- 2021-09-28
- Results posted
- 2021-09-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03228017. Inclusion in this directory is not an endorsement.